Overview distribution of biopsy-proven renal diseases in the world
In 2006, Nair and Walker [2] wondered if IgA nephropathy (IgAN) was the most common primary glomerulopathy in the USA, as in European and Asian areas. Analysing 5 years of renal biopsies from a referral centre serving most of the mid-western and southern states, they found that IgAN was the most common primary glomerulopathy in young adult Caucasians and the most common cause of end-stage renal disease (ESRD), while it was rare in African Americans in whom focal and segmental glomerulosclerosis (FSGS) remained more common.
The same results were found by Swaminathan et al. [3] evaluating the incidence of glomerular diseases in Olmest County, Minnesota. IgAN was the most frequent followed by FSGS, which was the leading cause of nephrotic syndrome in white adults, and then membranous nephropathy (MN).
In Brazil, as Polito et al. [1] report in their paper, FSGS is the most frequent among primary glomerulonephritides, followed by MN and IgAN. Lupus nephritis (LN) is the most common secondary form followed by post-infectious glomerulonephritis whose frequency is decreasing in most industrialized countries but remain high in some developing communities as shown by Kanjanabuch et al. [4] . Primary glomerulonephritides represent approximately half of all native renal biopsies, similar to almost all databases. Moreover, FSGS is the most common glomerulonephritis in children, adolescents, young adults and adults, while MN predominated in the elderly. Coppo et al. [5] , in the Italian Registry of Renal Biopsy, described IgAN as the most frequent biopsy-proven renal disease among children.
As for Europe, IgAN is the most frequent primary glomerulonephritis in Italy [6, 7] , Spain [8] , Czech Republic [9] , France [10] and Hungary [11] , while MN is the most frequent in Macedonia [12] , membranoproliferative glomerulonephritis (MPGN) in Romania [13] and nonIgA mesangioproliferative glomerulonephritis in Serbia [14] . LN is the most frequent among the secondary forms (Table 1) .
IgAN is the most common biopsy-proven renal disease among primary glomerulonephritides in Asia as well, as described in reports from China [15] , Japan [16] and Korea [17] and LN is the most frequent among the secondary forms.
In the Middle East, FSGS is the most frequent renal disease in the Saudi Arabian Registry, followed by MPGN. IgAN accounts for only 6.5%, while LN is the most common secondary form [18] .
Briganti et al. [19] , in 2001, studied the incidence of glomerulonephritis in Australia and they found that IgAN, FSGS, LN and vasculitis were the most common renal diseases in adults with a male predominance for all glomerulonephritides except LN.
The clinical features of the different forms of glomerulonephritis do not differ much across the different countries.
The health programme of a country
The first step in a kidney disease screening programme is traditionally identified by urinalysis because it is easy to perform, cheap and reliable. In Japan, it became part of the annual health examination programme more than 30 years ago with the aim of early detection of glomerulonephritis and early referral to a nephrologist. After adding in 1992 the measurement of serum creatinine to the programme, a core screening schedule for kidney diseases was set up. As Imai et al. [20] showed in their report, in adopting such a nationwide-accepted screening programme, the increase in incidence of early referral to a nephrologist and eventually the decrease of ESRD incidence is consequential. Thus, the efforts should be concentrated on implementing cost-effective first-line panels for the early detection of kidney diseases in national health programmes. Serum creatinine measurement with estimated glomerular filtration rate (Cockcroft or MDRD formula) and urinalysis with microalbuminuria should not be missing as they easily guide the nephrologist to the next diagnostic steps. This approach is feasible and mandatory in developed countries. On the other hand, the efforts to set up a nephrological programme in developing countries such as Benin, Togo and Bolivia are much greater but still urgent as Plata et al. [21] show in their report. We have to take into account infections and different comorbidities influencing the development of glomerulonephritides or other kidney diseases.
Policy and registries of renal biopsy
The experience with the Italian Registry of Renal Biopsy has shown that the main reason to perform a renal biopsy is urinary abnormalities [6, 7] . In the paper of Polito et al. [1] , urinary abnormalities represent the second clinical indication to perform a biopsy after nephrotic syndrome. However, without an adequate screening programme, it would not be possible to define the effective incidence of a large proportion of glomerulonephritides characterized by asymptomatic urinary abnormalities at their early stage. The consequent renal biopsy defines the underlying disease and lets the nephrologist chose the proper clinical intervention and time follow-up. This consolidated strategy of preventive medicine is being indicated by the 'Kidney Disease: Improving Global Outcomes' initiative. The slice of chronic kidney disease burden constituted by glomerulonephritides would be lighted up by dissecting it through a thorough epidemiological approach. Developing a well-structured national registry to catalogue the histological findings by common diagnostic codes, like those suggested by the European Dialysis and Transplant Association, would provide many benefits both for developed and developing countries. Setting up a renal biopsy registry could provide highly valuable data, which are useful for several purposes ranging from the correct epidemiological description and clinical correlations to the development of protocols for preventive medicine. Moreover, combining data with renal replacement therapy registries would allow us to evaluate the long-term outcome of patients with kidney disease.
Actually, it is not easy to compare the results of the analysis of different databases across the different countries also because of the different policy in biopsy practice. Hanko et al. [22] has recently analysed the changing pattern of adult primary glomerular disease in a single UK region in 30 years. They noticed that the biopsy rates increased significantly from 2.02 to 7.08 per hundred thousand population per year (php/year) and reported international biopsy rates ranging from 21.5 php/year in Australia to 1.1 php/year in Romania.
These data clearly show that policy in renal biopsy practice plays an important role. However, a regional renal biopsy registry may be a modern and easy tool for programming the early referral to a nephrologist and consequently reduce the chronic kidney disease burden which is represented by ∼10% of the population in developed countries (i.e. 50 million individuals in the European Union-27 countries). 
